Publications by authors named "O Egbuna"
Introduction: Toxic gain-of-function () variants contribute to the development of proteinuric nephropathies collectively referred to as APOL1-mediated kidney disease (AMKD). Despite standard-of-care treatments, patients with AMKD experience accelerated progression to end-stage kidney disease. The identification of two variants as the genetic cause of AMKD inspired development of inaxaplin, an inhibitor of APOL1 channel activity that reduces proteinuria in patients with AMKD.
View Article and Find Full Text PDFArticle Synopsis
- Individuals with specific genetic variants of apolipoprotein L1 are more likely to develop severe kidney disease, but effective treatments are currently unavailable.
- The research evaluated the small-molecule compound inaxaplin for its ability to inhibit the harmful effects of these variants in kidney cells and assessed its impact on proteinuria in a clinical trial involving patients with kidney disease.
- Results showed that inaxaplin significantly reduced urinary protein levels in a majority of the patients who adhered to the treatment, indicating its potential as a therapeutic option for affected individuals.
Objective: Evolocumab, a human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), markedly reduces low-density lipoprotein cholesterol (LDL-C). Here we characterize the pharmacokinetics, pharmacodynamics, safety, and tolerability of evolocumab manufactured at a new site administered in healthy Chinese subjects.
Materials And Methods: This phase 1 study of a single subcutaneous 140-mg dose of evolocumab was conducted in healthy subjects of Chinese descent residing in Hong Kong.
Background: Romosozumab is an antibody that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. A double-blinded, randomized, phase-2, dose-finding trial was performed to evaluate the effect of romosozumab on the radiographic and clinical outcomes of surgical fixation of tibial diaphyseal fractures.
Methods: Patients (18 to 82 years old) were randomized 3:1:1:1:1:1:1:1:1:1 to a placebo or 1 of 9 romosozumab treatment groups.